Lymph Node Ratio and Kras Mutation in R Colon Cancer

Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04342676

Enrollment

433

Registered

2020-04-13

Start date

2017-03-10

Completion date

2019-08-26

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer Stage III

Brief summary

clinical impact of LN ratio with Kras expression in colon cancer

Detailed description

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Interventions

DEVICEk ras

K ras

DRUGPanitumumab

vectibex in stage iv

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Stage III colon cancer

Exclusion criteria

* Stage I, II, IV

Design outcomes

Primary

Measure	Time frame	Description
LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).	2 years	impact on response

Secondary

Measure	Time frame	Description
LNR and K ras were evaluated and ASSOCIATION with PFS and OS.	2 years	impact on survival

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026